Form D · Biotechnology
Rose Therapeutics, Inc.
Norristown, PA · CIK 0001944189
Offering snapshot reported Sep 2, 2022 · SEC filing
- Reported sold
- $650K Offering amount: $1M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 22, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 2, 2022 | Initial | $650,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-457875
Source: Form D, filed Sep 2, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Timothy Langloss | Director, Executive |
| Ira Sanders | Director |
| Matthew Wotiz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
20 West Main Street, 3 Rd Floor
Norristown, PA, 19401
Norristown, PA, 19401